Gregor Verhoef - Concepedia

Author

Gregor Verhoef

Also Known As

G E Verhoef, G Verhoef, Gregor E Verhoef, Gregor E. G. Verhoef, Gregor E. Verhoef, Gregor E.G Verhoef, Gregor E.G. Verhoef, Gregor EG Verhoef, Gregor Verhoef, Iwona Wlodarska

366

Publications

23K

Citations

H-Index

Concepts

All Affiliations

KU Leuven Universitair Ziekenhuis Leuven Erasmus MC Erasmus University Rotterdam The University of Texas MD Anderson Cancer Center

About

Gregor Verhoef is an author at KU Leuven specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	36	3.5K
2	Health Sciences	19	21	1.9K
3	Arts	1	1	24
4	Public Health	1	1	24
5	Blood Transplantation	1	1	129

Gregor Verhoef

123

Publications

21.7K

Citations

H-Index

Page 1

	Year	Citations
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Stephen G. O’Brien, François Guilhot, Richard A. Larson, New England Journal of Medicine	2003	3.5K
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Brian Druker, François Guilhot, Stephen G. O’Brien, New England Journal of Medicine	2006	3.5K
A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome Jan Cools, Daniel J. DeAngelo, Jason Gotlib, New England Journal of Medicine	2003	1.7K
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia Bob Löwenberg, Gert J. Ossenkoppele, Wim van Putten, New England Journal of Medicine	2009	818
Acquired mutations in TET2 are common in myelodysplastic syndromes Saskia Langemeijer, Roland P. Kuiper, M Berends, Nature Genetics Hematological MalignancyGenetic DisorderMedicineGeneticsHematology	2009	740
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef, Journal of Clinical Oncology	2009	639
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study Lucien Noens, Marie-Anne van Lierde, R. De Bock, Blood	2009	606
ALK+ lymphoma: clinico-pathological findings and outcome. Brunangelo Falini, Stefano Pileri, Pier Luigi Zinzani, PubMed	1999	567
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse Dimitri Breems, Wim L.J. van Putten, Peter C. Huijgens, Journal of Clinical Oncology	2005	510
Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([<sup>18</sup>F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [<sup>18</sup>F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods? Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Journal of Clinical Oncology	2001	466

Page 1